CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: To demonstrate if targeting DHODH activity could alter the cellular metabolism, 630 metabolites were quantified after treatment of CML CD34+ cells with 100 nM Meds433 for 3 days.